James Kent | Specialist Procurement Pharmacist London & East of England
NHS England

James Kent, Specialist Procurement Pharmacist  London & East of England, NHS England

James Kent worked for many years within the acute sector of the NHS, most recently as Clinical Lead Pharmacist and later Chief Pharmacist at Southend Hospital NHS Trust. From 2011-2017 he was also seconded to an organisation called PrescQIPP as the Secondary Care  Lead. This organisation seeks to support the NHS Medicines Optimisation agenda through the delivery of evidence based resources. This role allowed him to focus on a variety of key topics, the most significant of which was the introduction of biosimilars within the NHS.
James now works as the  Regional Medicines Procurement Specialist for London and the East of England. This position has allowed James to continue on his mission to maximise biosimilar usage for the benefit of both NHS providers and commissioners. This work is facilitated by his membership of the National Biosimilars Programme Board. He is also the Chair of the Branded and Biosimilars Subgroup which sits under the Pharmaceutical Market Support Group (PMSG).


Biosimilars Day 1 - Monday 29th October 2018 @ 09:40

International stakeholders panel discussion: What lessons have we learnt in the last 12 months?

Consisting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
  • Experiences with Rituximab: how far from the uptake in the oncology space was Rituximab and why?
  • What lessons have we learnt with the move of biosimilars into oncology?
  • How does this impact on current understanding and future predictions of biosimilars uptake?
  • What does this mean for the recent European patent expiry of adalimumab?
  • How this will impact for adalimumab launch and for expectations over the next 6-12 months?
  • We have evidence that biosimilars impact healthcare systems sustainability, how do we then prove that this can or will improve patient access to the biosimilar opportunity?
last published: 29/Oct/18 16:25 GMT
last published: 29/Oct/18 16:25 GMT

back to speakers

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October

Sign Up for Event Updates